124 related articles for article (PubMed ID: 34535408)
1. Developing sustainable workflows for community pharmacy-based SARS-CoV-2 testing.
O'Connor SK; Healey P; Mark N; Adams JL; Robinson R; Nguyen E
J Am Pharm Assoc (2003); 2022; 62(1):253-259. PubMed ID: 34535408
[TBL] [Abstract][Full Text] [Related]
2. Implementing an integrated care management program in community pharmacies: A focus on medication management services.
Smith MG; Ferreri SP; Brown P; Wines K; Shea CM; Pfeiffenberger TM
J Am Pharm Assoc (2003); 2017; 57(2):229-235.e1. PubMed ID: 28173993
[TBL] [Abstract][Full Text] [Related]
3. Community Pharmacy Credentialing for Medical Insurance to Facilitate Sustainability in COVID-19 Testing.
Nguyen E; Healey PM; Robinson R; Adams JL; O'Connor SK
J Pharm Pract; 2023 Oct; 36(5):1108-1112. PubMed ID: 35414327
[No Abstract] [Full Text] [Related]
4. Financial impact of patients enrolled in a medication adherence program at an independent community pharmacy.
Clifton CL; Branham AR; Hayes HH; Moose JS; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S109-S113. PubMed ID: 30006182
[TBL] [Abstract][Full Text] [Related]
5. Community-Based Testing Sites for SARS-CoV-2 - United States, March 2020-November 2021.
Miller MF; Shi M; Motsinger-Reif A; Weinberg CR; Miller JD; Nichols E
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1706-1711. PubMed ID: 34882655
[TBL] [Abstract][Full Text] [Related]
6. Implementation of technician-driven medication therapy management program in community pharmacies.
Burnside TPT; Scott NJ; Smith MG
J Am Pharm Assoc (2003); 2019; 59(4S):S156-S160.e2. PubMed ID: 31326039
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of SARS-CoV-2 antibodies among North Dakota community pharmacy personnel: A seroprevalence survey.
Johnson A; Vincent B; Carson P; Skoy E
J Am Pharm Assoc (2003); 2021; 61(3):e127-e132. PubMed ID: 33568267
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical care in community pharmacies: practice and research in the US.
Christensen DB; Farris KB
Ann Pharmacother; 2006; 40(7-8):1400-6. PubMed ID: 16868221
[TBL] [Abstract][Full Text] [Related]
9. Reliability and validity of the Malay version of the drive-thru community pharmacy service questionnaire and the Malaysian public's awareness, attitudes, and perceptions of drive-thru community pharmacy during COVID-19.
Ababneh BF; Ong SC; Alsaloumi L; Aljamal HZ; Hussain R
J Pharm Policy Pract; 2023 Nov; 16(1):159. PubMed ID: 38017584
[TBL] [Abstract][Full Text] [Related]
10. Awareness, attitudes, and perceptions of drive-thru community pharmacy services among the general public in Malaysia during COVID-19: A cross-sectional study.
Ababneh BF; Ong SC; Hussain R
PLoS One; 2023; 18(3):e0282991. PubMed ID: 36897873
[TBL] [Abstract][Full Text] [Related]
11. Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains.
Green TC; Silcox J; Bolivar D; Gray M; Floyd AS; Irwin AN; Hansen RN; Hartung DM; Bratberg J
J Am Pharm Assoc (2003); 2024; 64(1):71-78. PubMed ID: 37863398
[TBL] [Abstract][Full Text] [Related]
12. Iowa community pharmacies' experiences with Medicaid managed care.
Urmie JM; Murry LT; Deng H; Doucette WR
J Am Pharm Assoc (2003); 2020; 60(4):624-630. PubMed ID: 31901442
[TBL] [Abstract][Full Text] [Related]
13. Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery.
Spence R; Sisson EM; Dixon DL
J Am Pharm Assoc (2003); 2022; 62(5):1581-1586. PubMed ID: 35461779
[TBL] [Abstract][Full Text] [Related]
14. Rural community pharmacies' preparedness for and responses to COVID-19.
Carpenter DM; Hastings T; Westrick S; Rosenthal M; Mashburn P; Kiser S; Shepherd JG; Curran G
Res Social Adm Pharm; 2021 Jul; 17(7):1327-1331. PubMed ID: 34155979
[TBL] [Abstract][Full Text] [Related]
15. A pharmacy-based referral program to assist low-income Medicare beneficiaries.
Hastings TJ; Hohmann LA; Neal J; Westrick SC
J Am Pharm Assoc (2003); 2019; 59(3):416-422. PubMed ID: 30826302
[TBL] [Abstract][Full Text] [Related]
16. HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
Weidle PJ; Lecher S; Botts LW; Jones L; Spach DH; Alvarez J; Jones R; Thomas V
J Am Pharm Assoc (2003); 2014; 54(5):486-92. PubMed ID: 25216878
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist provider status: Geoprocessing analysis of pharmacy locations, medically underserved areas, populations, and health professional shortage areas.
Murphy EM; West L; Jindal N
J Am Pharm Assoc (2003); 2021; 61(6):651-660.e1. PubMed ID: 34531121
[TBL] [Abstract][Full Text] [Related]
18. Keeping the "continuous" in continuous quality improvement: exploring perceived outcomes of CQI program use in community pharmacy.
Boyle TA; Bishop AC; Duggan K; Reid C; Mahaffey T; MacKinnon NJ; Mahaffey A
Res Social Adm Pharm; 2014; 10(1):45-57. PubMed ID: 23528447
[TBL] [Abstract][Full Text] [Related]
19. Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality.
Academy of Managed Care Pharmacy ; American Pharmacists Association
J Am Pharm Assoc (2003); 2014; 54(3):228-40. PubMed ID: 24770440
[TBL] [Abstract][Full Text] [Related]
20. Time and motion study of hepatitis C virus point-of-care testing in community pharmacies.
Beuschel T; Gootee E; Jordan M; Sikkenga T; Klepser DG; Holmquist H; de Voest A; Klepser ME
J Am Pharm Assoc (2003); 2023; 63(1):435-439. PubMed ID: 36463010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
